Table 2.
Tests | Type of Extract, Dose and Dosage | Biological Activities | Test Cell Lines/Organisms | References |
In vitro | Ethanolic extract, H. erinaceus fruiting bodies | promotion of NGF mRNA expression in a concentration-dependent manner through activation of the JNK pathway | 1321N1 human astrocytoma cells | [36] |
Ethanolic extract, H. erinaceus mycelia | inhibited the cell cycle G1 distribution as a result of the generation of the ROS and mTOR/p70S6K/NF-κB/p21 pathway | human colon cancer cell line DLD-1 (CCL-221) and human colorectal carcinoma cell line HCT-116 (CCL-247) | [113] | |
Ethanolic extract, H. erinaceus mycelia, and a solution of erinacine A | modulate multiple signalling pathways involved in neuronal survival and cell death pathways | Neuro-2a cells | [23] | |
Ethanolic extract, H. erinaceus mycelia enriched erinacine A | exerted an anti-apoptotic function by modulating the transcription factors p53 and NF-κB and their downstream events in cell lines, | neuroblastoma K-N-SHMJD78 cells | [114] | |
enhancing neurite growth of primary cortical neurons in a dose-dependent manner | primary cultures of neonatal rat cortical neuronal cells | [96] | ||
Ethanolic and hot water extract, H. erinaceus mycelia | exerted potent neuroprotection and NO-suppressing anti-inflammatory activity | HT22 cells | [115] | |
Ethanolic extract from H. erinaceus | promoted the normal cultivation of the nerve and glial cells; influence on the process of myelination |
cultured of WISTAR rat cerebellum cells | [116] | |
Methanolic extract, H. erinaceus fruiting bodies | inhibitory effects against cellular senescence in human primary cells, | Human dermal fibroblasts (HDFs), human umbilical vein endothelial cells (HUVECs), endothelial cell growth medium-2(EGM-2) | [117] | |
Aqueous extract, H. erinaceus fruiting bodies | induced 45.67 ± 0.79 pg/mL NGF synthesis * increased neurite extension |
NG108-15 cells | [2,55] | |
the protective abilities of H. erinaceus treatment and its combination with NGF were significantly higher than NGF treatment alone | mouse PNI model | [56] | ||
Aqueous extract of Malaysian-grown H. erinaceus | increase neurite extension; protective effect against oxidative stress |
NG108-15 cells | [2] | |
neuroprotective effects against high-dose corticosterone-induced oxidative stress | PC12 cells | [118] | ||
Aqueous extract, H. erinaceus mycelia and fruiting body, garlic extract | have the synergistic effect of the mycelium and garlic extracts on neuroprotective activity | PC12 cells | [119] | |
Aqueous extract, H. erinaceus mycelium | neuroprotective effect | an L-Glu-induced DPC12 cellular apoptosis model | [60] | |
AuNPs using the hot aqueous extract of H. erinaceus fruiting bodies | have potential neuronal differentiation and stimulated neurite outgrowth | PC12 cells | [120] | |
H. erinaceus biomass, a powder containing mycelium and primordia | increased PC12 cell survival against DEHP insult; induces anti-apoptotic activity; reduces intracellular reactive oxygen species levels |
PC12 cultured in DMEM | [121] | |
Enzymatic hydrolysates from H. erinaceus | more effective antioxidative and superoxide radical scavenging activity (compared to water and organic solvent extracts); neuroprotective effects against H2O2 |
PC12 cells | [122] | |
Biopolymer from the liquid culture broth of H. erinaceus mycelium | enhanced the growth of rat adrenal nerve cells; both nerve growth factors also improved the growth of PC12 cells |
PC12 cells | [58] | |
Polysaccharide extracts from fruiting bodies H. erinaceus | antioxidant and neuroprotective effects on Aβ-induced neurotoxicity in neurons | PC12 cells | [59] | |
In vivo | A solution of erinacine A (8 mg/kg body weight) dissolved in 5% ethanol and saline phosphate buffer, IGAS | Enhanced NGF and catecholamine secretion in the LC and hippocampus, and a decrease in the cerebral cortex | normal Wistar rats | [123] |
Ethanolic extract, H. erinaceus mycelia (50, 300, and 1000 mg/kg body weight), PO, and a solution of erinacine A (1, 5, and 10 mg/kg), IP for 5 days | reduced infarcted volume in the cortex and subcortex; reduced levels of proinflammatory cytokines such as iNOS, IL-1β, IL-6, and TNF-α in the serum |
ischemic stroke in Sprague-Dawley rat | [20] | |
A solution of erinacine A (1, 2, and 5 mg/day) for 5 days, IP | decreased the growth of the xenografts of CRC cells in nude mice by inhibiting cell proliferation and promoting apoptosis | BALB/c-nu mice | [113] | |
Ethanolic extract, H. erinaceus mycelia (10.76 mg and 21.52 mg), PO, and a solution of erinacine A (1 mg/kg body weight) IP for 5 days | the signalling molecules affected by erinacine A included the survival factors PAK1, cdc42, AKT, LIMK2, ERK, and Cofilin, IRE1á, TRAF2, ASK1, GADD45, and p21; a reduced number of apoptotic neurons |
C57BL/6 mice | [23] | |
Ethanolic extract, H. erinaceus mycelia, a solution of erinacine A and S (30 mg/kg/day) for 30 days, PO | reduced amyloid plaque burden in the cerebral cortex; increased the level of insulin-degrading enzyme (IDE) in the cerebral cortex |
APPswe/PS1dE9 transgenic mice | [52] | |
Ethanolic extract, H. erinaceus mycelia enriched erinacine A, PO | exerted an anti-apoptotic function by modulating the transcription factors p53 and NF-κB and their downstream events in Drosophila models of SCA3 disturbed by oxidative stress | Drosophila models of SCA3 (fly stocks, elav-Gal4, UAS-MJDtr-Q27, and UAS-MJDtr-Q78 flies) | [114] | |
300 mg/kg/day of mycelia powder and ethanolic extract for 30 days, PO | reduced amyloid plaque burden in the area, including the cerebral cortex and hippocampus; increased NGF/proNGF ratio; and promoted hippocampal neurogenesis |
5-month-old female APPswe/PS1dE9 transgenic mice | [22] | |
Erinacine A- enriched H. erinaceus mycelia (108, 215, and 431 mg/kg/day) for 13 weeks, PO | lower oxidative stress significantly improved learning and memory |
3-month-old male and female senescence-accelerated mice (SAMP8) | [53] | |
Ethanolic extract, H. erinaceus (20 and 60 mg/kg) for 28 days, PO | increased hippocampal neurogenesis | male C57BL-6J mice | [27] | |
Ethanolic extract of H. erinaceus (60, 120, and 300 mg/ kg body weight) for 21 days, PO | a reduction of COX2-expressing astrocytes; neuroprotective effect |
male C57BL mice (a pilocarpine-induced SE model) | [124] | |
An ethanolic mixture of lyophilized mycelium and sporophores of H. erinaceus (1 mg/supplement per day) for 2 months, PO | Increased recognition and memory performance in mice during aging; reduced cognitive decline |
male C57BL-6J mice | [31] | |
Methanolic extract, H. erinaceus mycelia (1 g/ kg), and a solution of erinacine A (43 mg/kg) for 18 weeks, PO | decreased neuronal loss; higher NGF biosynthesis; performed better in spatial learning; increased mRNA expression levels of TNFa and IL-1b in the hippocampus |
C57BL/6 mice | [54] | |
5% freeze-dried powder of fruiting bodies of H. erinaceus, PO | increased NGF mRNA in the hippocampus | male ddY mice | [36] | |
Powder of H. erinaceus mycelia (100, 200, and 400 mg/kg body weight) for 4 weeks, PO | antidepressant-like effect; increased BDNF, TrκB, and PI3K expressions in the hippocampus; reduced IL-6 and TNF-α levels |
restraint stress-induced depression in ICR mice | [26] | |
400 mg mycelia and 100 mg dried fruiting body extract of H. erinaceus for 2 months, PO | increasing glutamatergic synaptic drive in the hippocampus; increased general locomotor activity but did not affect spatial memory |
C57BL-6J mice | [57] | |
The powdered fruiting bodies of H. erinaceus (5% w/w) for 23 days, PO | prevented the cognitive deficits induced by the administration of Aβ(25–35) | male 5-week-old ICR mice | [34] | |
The powdered mycelia of H. erinaceus (0.1 g/kg, 0.3 g/kg, and 1 g/kg) for 30 days, PO | reduced oxidative stress; increase in dopamine levels |
male C57BL/6Narl mice treated with 1-methyl-4-phenylpyridinium (MPTP) |
[125] | |
H. erinaceus biomass, a powder containing mycelium and primordia (200 mg/kg body weight) for 3 months, IGAS | neuroprotective effect; increased expression of genes, particularly HSP70, HO-1, and TRX), leading to an increase in LXA4 synthesis in various regions of the brain. |
male Sprague-Dawley rats | [61] | |
Aqueous extract, Malaysian-grown H. erinaceus fruiting bodies (10 or 20 mL kg−1 body weight per day) for 14 days, PO | promote the regeneration of injured rat peroneal nerves in the early stages of recovery | adult female Sprague-Dawley rats | [50] | |
Aqueous extract, H. erinaceus fruiting bodies, for 14 days, PO | increased level of NGF in cortex, striatum and hippocampus | male ddY mice subjected to MCA Occlusion | [33] | |
Aqueous extract, H. erinaceus mycelium (0.3, 1, and 3 g/kg body weight) for 4 weeks, PO | neuroprotective effect | AD mouse | [60] | |
The supplement Micotherapy Hericium (Noceto, Parma, Italy) (contains mycelium and fruiting body extract of Hericium erinaceus in a ratio of 4/1), corresponding to 0.025 g/g body weight for 2 months, PO | increasing glutamatergic synaptic drive, novelty exploration behaviour, and recognition memory in the hippocampus | C57BL-6J mice | [126] | |
Supplementation of H. erinaceus (Host Defense Mushrooms, Fungi Perfecti, LLC., Olympia, WA, USA) through wet food for 4 months, PO | anxiolytic effects; no improvements in spatial memory |
rTg4510 tau mouse model | [127] | |
In vivo/ Clinical trial |
Aqueous and ethanolic extract, H. erinaceus supplementation (80% mycelia and 20% fruiting body), 1.2 g per capsule; 3 capsules/day for 8 weeks; PO | decreased depression, anxiety, and sleep disorders | seventy-seven volunteers (62 females and 15 males) with a body mass index (BMI) ≥ 25 kg/m2 | [37] |
Aqueous extract, H. erinaceus mycelium, 350 mg/capsule containing 5 mg/g erinacine A (EAHE) for 49 weeks; PO | reduced cognitive decline | patients with age > 50 years and diagnosis of probable AD | [51] | |
Dried fruiting bodies of H. erinaceus, 250 mg tablets containing 96% of H. erinaceus dry powder three times a day for 16 weeks, PO | improved cognitive function | a double-blind, parallel-group, placebo-controlled trial was performed on 50- to 80-year-old Japanese men and women diagnosed with mild cognitive impairment | [21] | |
0.8 g of the powdered fruiting body of H. erinaceus; 4 capsules/day for 12 weeks; PO | improved cognitive function | randomized, double-blind, placebo-controlled parallel-group | [128] | |
5 g/day of the lyophilized H. erinaceus for a 6-month period; PO | improved cognitive function | fifty elderly individuals with disabilities | [129] | |
Aqueous extract, 0.5 g of the powdered fruiting bodies of H. erinaceus per cookie, 4 cookies daily for 4 weeks; PO | decreased depression, anxiety | a double-blind, parallel-group, placebo-controlled trial was performed on thirty middle-aged females in menopause | [130] | |
Patented extraction, Amycenone®, H. erinaceus fruiting body extract (0.5% hericenones and 6% amyloban), 1950 mg/tablet (Amyloban® 3399) 6 tablets, divided into 2 or 3 doses /day for 6 months; PO | improved cognitive function | 86-year-old male patient | [131] | |
Patented extraction, Amycenone®, H. erinaceus fruiting body extract (0.5% hericenones and 6% amyloban), 1950 mg/tablet (Amyloban® 3399) 6 tablets, divided into 2 or 3 doses /day for 4 weeks; PO | decreased depression, anxiety, and sleep disorders | 8 female healthy participants | [132] |
* The amounts of NGF secreted into the culture medium.